Latest News

As global markets continue to navigate a complex landscape, U.S. stocks have shown resilience by rallying at the start of the year, with small-cap and value shares leading the charge. In this context, penny stocks—often overlooked yet still significant—represent an intriguing investment area for those seeking growth opportunities in smaller or newer companies. Despite being considered a niche market, these stocks can offer substantial returns when backed by robust financial health. Let's...

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...

Key Insights Insiders appear to have a vested interest in Blau Farmacêutica's growth, as seen by their sizeable...

Recent coverage has highlighted how ownership concentration and broad shareholder participation at Northern Minerals is shaping governance and strategic influence in its long‑dated mining projects. This focus on who holds power in the register offers investors a clearer view of how decisions may be made and aligned across stakeholders. Next, we examine how this growing interest in Northern Minerals’ ownership structure could influence the company’s broader investment narrative. Uncover the...

In early January 2026, Caris Life Sciences announced a partnership with digital health company Everlywell to launch Caris Detect, a multi-cancer early detection blood test that applies whole genome sequencing and AI to identify molecular signals of cancer in the bloodstream, with commercialization planned through Everlywell’s platform in the first half of 2026. This collaboration highlights how advanced genomic screening and consumer-focused digital health distribution could broaden access...

If you are wondering whether IMAX at around US$35.07 is still good value after its run, this article will walk through what the current share price might be implying. The stock has had a mixed run recently, with a 2.8% gain over the last week, a 10.2% decline over the last month, and returns of 54.0% over 1 year, 120.6% over 3 years, and 88.3% over 5 years. Recent attention on IMAX has centered on box office trends and its position in premium large format cinema, as investors assess how...

Tasmea (ASX:TEA) is back on investors’ radars after a fresh update on its equity-based staff incentives, which puts governance transparency and capital consistency at the center of the story. See our latest analysis for Tasmea. The update on equity incentives comes as Tasmea’s 1 day share price return of 2.93% and 7 day share price return of 10.68% sit against a year to date share price return of 8.83% and a 1 year total shareholder return of 63.41%. Together, these figures point to momentum...

Duos Technologies Group, through its Duos Edge AI subsidiary, recently deployed a patented modular Edge Data Center in Hereford, Texas, in partnership with the Hereford Independent School District to bolster low-latency computing for education and local users. This initiative highlights Duos’ push into rural and underserved markets, using repeatable, capital-efficient edge infrastructure that targets recurring revenue and broader digital access. We’ll now examine how this rural edge data...

If you are wondering whether Warrior Met Coal's current price reflects its true worth, you are not alone. The stock invites a closer look at what you are actually paying for the underlying business. At a recent close of US$102.08, the share price sits alongside returns of 11.2% over 7 days, 22.2% over 30 days, 14.0% year to date and 90.5% over 1 year, with a very large gain over 5 years. These price moves sit against ongoing interest in coal producers and how investors are weighing long term...

Most Gulf markets have recently retreated due to geopolitical tensions, despite expectations of U.S. interest rate cuts following slightly lower-than-expected inflation data. In such a climate, investors often seek opportunities that offer potential growth at lower price points, which is where penny stocks come into play. Although the term "penny stocks" may seem outdated, these smaller or newer companies can present unique investment opportunities by combining strong balance sheets and solid...

In recent weeks, Middle Eastern stock markets have experienced fluctuations largely due to geopolitical tensions and oil price volatility, with most Gulf markets retreating despite some positive economic indicators like lower-than-expected U.S. inflation data. Amidst this backdrop, identifying stocks with strong fundamentals becomes crucial for navigating the complexities of these markets and uncovering potential opportunities.

If you are wondering whether Old National Bancorp at around US$22.85 is offering fair value or a potential opportunity, it helps to step back and look at what the recent share performance is really telling you. The stock price return data is mixed, with a 0.8% decline over the past 7 days and a 0.6% decline over 30 days, set against gains of 1.3% year to date, 3.0% over 1 year, 41.0% over 3 years, and 48.2% over 5 years. These moves sit against a backdrop where investors are continuously...

Clinuvel Pharmaceuticals (ASX:CUV) has started dosing patients in a preclinical study of its VLRX-L controlled-release liquid injectable peptide platform. This marks its first next-generation delivery technology to enter formal preclinical testing. See our latest analysis for Clinuvel Pharmaceuticals. The VLRX-L preclinical milestone comes as the share price sits at A$12.75, with a 1-day share price return of 4.25% and a 90-day share price return of 10.29%, while the 1-year total shareholder...

If you are wondering whether FTI Consulting at around US$175 per share is offering fair value or a potential mispricing, you are not alone. The stock has been relatively steady in the short term, with a 0.4% decline over the last 7 days, a 2.8% return over the last month, and a 2.9% return year to date. This sits alongside a 9.2% decline over the last year, but gains of 13.0% over 3 years and 50.2% over 5 years. Recent attention on FTI Consulting has reflected how the market is reassessing...

GSI Technology has announced a government-funded proof-of-concept with Israel’s G2 Tech and two agencies, including the U.S. Department of War, to integrate its Gemini-II compute-in-memory APU into Sentinel, an autonomous perimeter security system coordinating drones and cameras for real-time monitoring and response. Around US$1,000,000 in expected funding to optimize and integrate Gemini-II into a mission-critical defense application underscores the technology’s relevance for on-device AI...

If you are wondering whether Grab Holdings is offering fair value at its recent price of US$4.63, you are not alone. This article is built to help you frame that question clearly. The share price has seen a 8.9% decline over the last week and a 7.8% decline over the past month, although it is up 3.8% over 1 year and 24.8% over 3 years, while still sitting 68.9% below its 5 year level. These moves come as investors continue to weigh the prospects of Grab's core ride hailing, deliveries, and...

It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...

Key Insights Cellectis' significant individual investors ownership suggests that the key decisions are influenced by...

For many investors, the main point of stock picking is to generate higher returns than the overall market. But the risk...

Portage Ventures, part of Power Corporation of Canada, has expanded into secondary fintech investments by taking over management of Point72 Ventures’ portfolio of around 40 mature fintech companies in a new US$280 million fund. This move highlights Power Corp.’s push to grow its Sagard alternative asset platform and deepen its exposure to fee-based private-market fintech assets. We’ll now examine how Portage’s move into managing secondary fintech assets could influence Power Corp.’s...

If you are wondering whether Solventum is offering fair value or represents an opportunity on sale right now, this article walks through what the current price might be indicating. The stock most recently closed at US$80.05, with returns of 11.1% over the past year, a 1.3% gain year to date, and declines of 5.0% over 7 days and 2.2% over 30 days. Recent headlines around Solventum have focused on its position within the healthcare sector and investor interest in how the business trades as a...

If you are wondering whether Stoke Therapeutics at around US$30.97 is still offering value or already pricing in a lot of optimism, you are not alone. The stock has seen a 226.3% return over the last year, although the past 7 days and 30 days brought declines of 11.9% and 6.1% respectively, and year to date it is close to flat at 0.2%. Recent attention on Stoke Therapeutics has centered on its position in the pharmaceuticals and biotech space, where investors often react quickly to clinical...

Bitmine Immersion Technologies (BMNR) has opened Q1 2026 with revenue of US$2.3 million and Basic EPS of a US$15.98 loss, while trailing 12 month figures show revenue of US$7.2 million and Basic EPS of a US$46.42 loss. Over the past year, revenue has moved from US$3.3 million in Q4 2024 to US$6.1 million on a trailing 12 month basis in Q4 2025, alongside a shift in Basic EPS from a US$1.32 loss to US$13.60. With the latest quarter firmly in loss making territory, the focus now is on how...

Why Hacksaw’s Pennsylvania launch is drawing investor attention Hacksaw (OM:HACK) is in focus after Hacksaw Gaming rolled out its titles in Pennsylvania, expanding an existing partnership with bet365 and distributing games via Light & Wonder to a new regulated US audience. See our latest analysis for Hacksaw. Despite the Pennsylvania expansion, momentum in Hacksaw’s share price has faded recently. The 7 day share price return is 9.9% and the 90 day share price return is 18.4%, leaving the SEK...